Alnylam’s AMVUTTRA just smashed a $1 billion revenue milestone in Q2—its first-ever—despite a revised full-year forecast, as demand normalizes from early hype. The company’s confidence remains high, focusing on AMVUTTRA as the gold standard for new patients and ramping up doctor adoption. Meanwhile, Alnylam is expanding into China, exploring AI-driven RNAi therapies, and launching trials for von Willebrand disease and Alzheimer’s—proving they’re building a future beyond one blockbuster drug.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
